Myriad Genetics INC 10-Q quarterly reports

Myriad Genetics reports a revenue decrease in Q2 2026 driven by estimate changes and reimbursement pressures, while increasing sales and marketing investments.

Myriad Genetics reported a 2.3% increase in revenue for the first quarter of 2026, reaching $200.4 million, but experienced a significant widening of its net loss to $34.1 million.

Myriad Genetics reported a wider net loss in the third quarter and first nine months of 2025, driven by significant goodwill and intangible asset impairment charges, despite some revenue growth in Hereditary Cancer and Prenatal segments.

Myriad Genetics reported a significant net loss in the second quarter of 2025, primarily driven by a $316.7 million goodwill and intangible asset impairment charge, despite slight revenue growth.

Myriad Genetics' Q1 2025 revenue decreased to $195.9 million, impacted by changes in pharmacogenomics coverage and leadership transitions.

Myriad Genetics saw an 11% year-over-year revenue increase in the third quarter of 2024, driven by growth in several testing segments, but faces potential revenue impacts due to a change in UnitedHealthcare's coverage policy for pharmacogenetic testing.

Myriad Genetics saw a 15% year-over-year increase in revenue for the second quarter of 2024, fueled by growth in prenatal and pharmacogenomics testing volumes and average revenue per test.

Myriad Genetics saw a 12% year-over-year increase in revenue for the first quarter of 2024, primarily driven by growth in testing volumes across its product lines.